NSIGHT2 Trial Finds No Difference in Diagnostic Rate Between WGS and WES

In a surprising result, a new clinical genomic trial in neonates in the NICU setting found no major difference in the diagnostic rate between...
MRSA bacteria or superbug

Genetic Study of MRSA IDs Patients With Highest Risk of Death

A GWAS of two important clonal types of Staphylococcus aureus using machine learning techniques finds predictors of poor infection outcomes
With NGS diagnostics

Illumina and Qiagen Enter 15-Year Diagnostics Partnership

Two leaders in genomics and molecular analysis, Illumina and QIAGEN, have announced a 15-year partnership that the companies say is aimed at increasing the...

Cepheid’s BCR-ABL Test Gets FDA Approval

Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid...
Source:Jill Lehmann Photography/Getty Images

Blood Test Identifies Preterm Birth Risk of Expectant Mothers

Stanford team IDs three sets of cfDNA in blood of pregnant women that measures risk of preterm delivery up to two months ahead of labor

Illumina Expands East, Opening ‘Solutions Center’ in Baltimore

Illumina said today it has opened its first commercial location on the East Coast, within the University of Maryland (UM) BioPark in Baltimore. The Illumina...
Myriad Genetics' myChoice HRD Plus test will be used by AstraZeneca in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with a combination of AZ’s Lynparza® (olaparib) and the Genentech (Roche) cancer drug Avastin® (bevacizumab). [Source: OGphoto / Getty Images]

AZ to Use Myriad’s myChoice HRD Plus Test in Phase III Trial

Myriad Genetics will use myChoice HRD Plus to evaluate patients enrolled in an ongoing Phase III trial, in order to identify HRD cases

10x Genomics Graduates from ‘Super Success’ to $100M IPO

10x Genomics has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities...

The Next Era in Pathway Proteomics: Turnkey Targeted Quantitation Workflows

REGISTER NOW Broadcast Date: October 1, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr)...
Could Based Genomics Data

Q-State Biosciences and 2bPrecise Sign Precision Medicine Deal

The Q-State Biosciences and 2bPrecise partnership aims to achieve improved diagnostic yields and patient outcomes by using clinical tools to match patients with precise therapies based on their health attributes and genetic profile.
Scroll Up